Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 10/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148544 | 0.94 | GPR17 (0.33) | GPR17P2RY2KMT2AMALT1ALDH1A1 | |
| SCHEMBL1148360 | 0.93 | GPR17 (0.36) | GPR17P2RY2MEN1KMT2AFLT1 | |
| SCHEMBL1147738 | 0.90 | GPR17 (0.37) | GPR17P2RY2MEN1KMT2AFLT1 | |
| SCHEMBL591460 | 0.89 | MALT1 (0.33) | MALT1 | |
| SCHEMBL1148352 | 0.89 | IDO1 (0.32) | F2MALT1 | |
| SCHEMBL1148374 | 0.89 | TSHR (0.35) | MALT1ALDH1A1 | |
| SCHEMBL1148386 | 0.89 | MALT1 (0.33) | MALT1 | |
| SCHEMBL1148230 | 0.88 | GPR17 (0.34) | GPR17P2RY2MEN1KMT2AFLT1 | |
| SCHEMBL1148301 | 0.88 | MALT1 (0.35) | GPR17P2RY2MEN1KMT2AEPHX2 | |
| SCHEMBL591565 | 0.87 | MALT1 (0.36) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264021-B1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264021-A1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | GPR17 4172/4885P2RY2 3126/4885MEN1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.